Core Viewpoint - Orchestra BioMed Holdings, Inc. announced a public offering of 9,413,637 shares at $2.75 per share, along with pre-funded warrants for 5,136,363 shares at $2.7499 each, aiming to raise approximately $40 million before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 2,182,500 shares at the public offering price [1]. - The expected closing date for the offering is August 4, 2025, subject to customary conditions [1]. Group 2: Use of Proceeds - The net proceeds will fund the atrioventricular interval modulation (AVIM) therapy program, the BACKBEAT study, and the Virtue Sirolimus AngioInfusion Balloon (SAB) program, along with general corporate purposes [2]. Group 3: Company Overview - Orchestra BioMed focuses on high-impact biomedical technologies through partnerships with leading medical device companies [6]. - The company’s lead product candidate, AVIM therapy, targets hypertension, while Virtue SAB addresses atherosclerotic artery disease [6]. - The company has strategic collaborations with Medtronic and Terumo for the development and commercialization of its key therapies [6].

Core Viewpoint - Orchestra BioMed Holdings, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the intention to use the proceeds for its AVIM therapy program, BACKBEAT study, and Virtue SAB program, among other corporate purposes [1][2]. Group 1: Offering Details - The offering includes common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the securities sold [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will fund the AVIM therapy program, the BACKBEAT study, the Virtue SAB program, and general corporate purposes [2]. Group 3: Company Overview - Orchestra BioMed is focused on accelerating high-impact biomedical technologies through partnerships with leading medical device companies [6]. - The company’s lead product candidate is AVIM therapy for hypertension, and it is also developing Virtue SAB for atherosclerotic artery disease [6]. - The company has strategic collaborations with Medtronic and Terumo for the development and commercialization of its key therapies [6].